Competition
Competitive Bottom Line
Tenet has one real moat and one commodity business, and the market still prices it as if both halves were commodities. The moat is USPI, the largest national ambulatory surgery platform by facility count (533 ASCs + 26 surgical hospitals across 37 states) — a physician-syndication network that is genuinely hard to replicate because the binding constraint is not capital but local orthopedic, GI, and cardiology partnerships. The commodity is the Hospital Operations segment, which competes head-to-head with HCA in San Antonio, El Paso, and Florida and is a price-taker on commercial managed-care contracts, Medicaid supplemental payments, and California labor laws.
The single competitor that matters most is HCA Healthcare: 3.6× the revenue, denser local market shares, materially better hospital-segment margin, and the only peer with a strategic ASC build (Sarah Cannon network) sized to threaten USPI's growth runway. Behind HCA, the relevant pressure on USPI is not from listed peers — it is from private vertical integrators: Optum/SCA Health (UnitedHealth-owned) and AmSurg/Envision-derived rollups, both of which Surgery Partners explicitly names as direct ASC competitors in its FY2025 10-K. The peer set delivers the read on Tenet's hospital margin durability; the unlisted competitors deliver the read on USPI's pricing and physician-retention runway.
One sentence to internalize: Tenet's moat is USPI's physician network, not its hospital footprint — and the competitors who can actually erode that moat are mostly private (Optum/SCA, AmSurg, hospital-system ASC joint ventures), which is why public peer compares understate the threat.
The Right Peer Set
Five public companies anchor the read on Tenet, organized by which segment they inform. HCA, UHS, and CYH triangulate Hospital Operations across three points of the operating spectrum (best-in-class scale, second-tier execution, stressed leverage). SGRY is the only listed pure-play comparable to USPI's ambulatory model and the cleanest market read on ASC unit economics. ACHC is the behavioral-hospital adjacent comp and the cycle-stress test for specialty acute care.
EV/EBITDA multiples are TTM and GAAP-derived (operating income + D&A) for cross-peer consistency, not company-reported "adjusted EBITDA." THC margin uses company-reported adj EBITDA. ACHC excluded from EV/EBITDA — TTM EBITDA went negative on FY2025 facility impairments. Market cap and EV reflect close on 2026-05-05.
The bubble chart reveals the central pricing puzzle. Tenet's blended margin (21.4%) is essentially equal to HCA's (21.8%) and well above UHS (16%), CYH (15%), and SGRY (17.7%) — yet Tenet trades at the same multiple as the stressed mid-tier hospital peers, not at the HCA scale-leader multiple or the SGRY ASC-pure-play multiple. That dislocation only makes sense if the market is treating Tenet purely as a hospital chain and assigning zero premium for the USPI ambulatory mix that is doing the work on margin. The peer set is precisely calibrated to tell you which read is correct — by comparing segment-level economics rather than blended consolidated print.
Why these five and not more. LifePoint (PE-owned by Apollo, ~60+ hospitals) is the most relevant rural peer but private. Ardent Health (ARDT) IPO'd July 2024 — too short a public history. Encompass Health (EHC) and Select Medical (SEM) are post-acute / rehab — adjacent, not substitutes. Non-profit systems (CommonSpirit, Ascension, AdventHealth) are huge in shared local markets but are not investable analogs because of tax exemption and bond economics. The five-peer set keeps evidence density per peer high.
Where The Company Wins
Tenet wins on four specific dimensions, each tied to a measurable line and a comparable peer.
Win 1: Only listed for-profit with a scaled ASC platform
USPI's 533 ASCs plus 26 surgical hospitals across 37 states is the largest national ambulatory footprint among public for-profits. HCA, the largest hospital operator, has 121 ASCs plus 31 endoscopy centers — meaningful but ~28% of USPI's facility count. Surgery Partners, the only listed ASC pure-play, has 157 ASCs + 19 surgical hospitals — ~33% of USPI's facility count. This matters because ASC growth is gated by physician partnerships, not capital, and the largest national operator has the highest probability of being the chosen platform partner when an orthopedic group decides to syndicate. The FY2025 10-K cites 35 acquired centers and 87 service-line additions (per Industry tab) as the operating cadence.
Win 2: Mix-driven margin parity with HCA at a fraction of the scale
Tenet's consolidated 21.4% adjusted EBITDA margin is almost identical to HCA's 21.8% GAAP-derived margin, despite Tenet being 1/3.6 the revenue. The reason is segment mix: USPI's ~40% segment EBITDA margin pulls Tenet's blend up, while HCA's hospital-heavier mix anchors its blend lower (its hospitals are still better-run on a like-for-like basis, but the consolidated print converges). Among hospital-focused peers, the gap is wider: UHS at 16.0%, CYH at 15.3%, SGRY at 17.7% — Tenet beats all three on consolidated margin.
The chart reveals what the consolidated number obscures: USPI by itself prints at 39.2% — more than double SGRY's blended 17.7% and roughly 2.5× UHS or CYH. This is the moat. SGRY is Tenet's closest economic parallel on the ambulatory side, but does it at considerably lower margin and with materially higher leverage (6.4× net debt / EBITDA vs. Tenet 2.25×).
Win 3: Cleanest balance sheet among scale peers
Tenet's 2.25× net debt / EBITDA (Q4 2025) is the lowest among scale peers ex-UHS. CYH runs at 5.5×+ with negative book equity. SGRY operates at 6.4×. ACHC sits around 3.5× but is impaired. HCA at 3.0× is close, but HCA is materially larger and produces more absolute FCF. The deleveraging story matters for two reasons: it gates the buyback cadence (Tenet retired ~22% of shares since 2022) and it lowers refinancing risk in an environment where UHS is explicitly flagging the 2026 refinancing of its 1.65% senior notes at "significantly higher interest rates" in its FY2025 MD&A.
Win 4: Cash conversion that the others can't match
Free cash flow was $321M in FY2022 and reached $2.53B in FY2025, with management guiding to $2.5–2.8B for 2026. SGRY converts almost zero of its EBITDA to FCF (high capex on de novo development). HCA generates ~$7.7B of FCF on $16.5B EBITDA (47% conversion) — strong but on a much larger denominator. Tenet converts ~55% of consolidated adjusted EBITDA to FCF before NCI distributions; ~35% after the ~$700M of annual NCI payments to physician partners. The post-NCI yield (~10% on equity) is the cleanest like-for-like measure and Tenet wins it on a per-dollar basis.
Takeaway: All four wins trace back to one root: USPI's physician-network density. The hospital cleanup (14 divestitures in 2024) reset the cost base and concentrated the footprint, but the durable advantage is the ASC mix — and the ASC mix is durable because reproducing USPI's 533-center, 37-state physician partnership graph would take a decade and a strategic acquirer with a deeper checkbook than SGRY currently has.
Where Competitors Are Better
Four specific gaps where Tenet trails. Be precise about which competitor is better and why — generic "competition is intense" language hides what matters.
Gap 1: HCA dominates hospital-segment density and physician alignment
HCA operates 190 hospitals (179 acute) across 19 states with much higher local market share in its core markets — Houston, Nashville, Denver, Las Vegas, Salt Lake City, multiple Florida MSAs. In shared markets like San Antonio (where Tenet's Baptist Health System overlaps with HCA-Methodist), HCA typically holds the #1 or #2 share position. The result is structural: HCA negotiates managed-care contracts with embedded leverage Tenet cannot match, and its same-facility hospital margin runs roughly 200–300 bps above Tenet's hospital segment (HCA segment disclosure does not separate, but consolidated 21.8% with smaller ASC contribution implies a hospital margin around 20%, vs. Tenet hospital segment 15.7%). HCA is also rolling out a single EHR platform across all facilities — a multi-year operating-leverage program Tenet has not signaled at the same scale.
Gap 2: SGRY's pure-play multiple is the gap Tenet cannot close
Surgery Partners trades at 9.4× EV/EBITDA on the same 17.7% margin business that Tenet's USPI segment runs at 39.2% margin. SGRY's higher multiple reflects (a) pure-play exposure to ASC migration with no hospital drag, (b) explicit physician-partner balance-sheet structure, and (c) higher M&A cadence relative to its size. Tenet's USPI is structurally better but earns no rerate inside the consolidated capital structure because the market discounts the hospital piece into the blended multiple. SGRY's recent FY2025 10-K explicitly names HCA, AmSurg, and Tenet as ASC competitors — confirming the market is thinking about USPI as a pure-play asset, not as a Tenet attribute.
Gap 3: UHS's behavioral diversification and lower leverage
UHS at 1.6× net debt / EBITDA is less levered than Tenet (2.25×) and runs a 339-facility behavioral health business across 39 states + UK + PR — a category Tenet exited via 2017–2020 divestitures. The behavioral segment is structurally counter-cyclical to acute-care payer mix and provides ~40% of UHS EBITDA. Behavioral was the area where Tenet historically underperformed (Aspire/Vanguard divestiture history, several DOJ settlements) and UHS's continued footprint is a strategic option Tenet no longer has. ACHC, the pure-play behavioral peer, is currently impaired (FY2025 EBITDA negative on facility goodwill writedowns) — meaning UHS is also taking share inside its own category.
Gap 4: SGRY and HCA out-acquire on ASC tuck-ins per dollar of revenue
SGRY's acquisition cadence (35–45 centers per year on a ~$3.2B revenue base) is materially higher per dollar of revenue than Tenet's (USPI added ~35 centers in 2025 on a ~$5.2B segment revenue). HCA has been quietly building Sarah Cannon Surgical Network as an ASC layer beneath its hospital footprint. Both are buying centers in geographies Tenet considers core (Texas, Florida, Tennessee), and both are willing to pay high multiples for physician relationships in priority markets. Tenet's discipline on price preserves margin but cedes some growth runway in metros where HCA-Sarah Cannon or SGRY locks in physicians first.
The gap that matters most: SGRY's pure-play multiple. The structural reality is that USPI is a better business than SGRY (more scale, higher margin, better cash conversion) but cannot earn SGRY's multiple while wrapped inside a hospital chain. The bull case requires the market to start valuing the parts separately; if it doesn't, the SOTP discount is permanent and Tenet caps out at a hospital-style ~6× multiple for the consolidated entity.
Threat Map
Six threats grouped by where they hit (USPI side, Hospital side, or both). The non-listed competitors — Optum/SCA Health, AmSurg/Envision-derived rollups, Apollo's LifePoint — are explicitly named as ASC competitors in Surgery Partners' FY2025 10-K and are the most underestimated category in the public peer comparison.
The two threats that change the thesis: (1) Optum/SCA Health using UNH's payer leverage to exclude USPI ASCs from narrow networks would be the single biggest blow to USPI same-facility growth — already partially visible in industry research mentions of "narrow networks" and "vertical integration." (2) OBBBA Medicaid implementation in non-expansion states where Tenet has 50%+ of beds could compress hospital segment EBITDA by $300-500M annually starting 2027. The first attacks the moat; the second compresses the commodity but doesn't erase it.
Moat Watchpoints
Five measurable signals that tell you whether Tenet's competitive position is improving or weakening. Each has a quarterly disclosure source so investors can track without a Bloomberg terminal.
The single number to watch: USPI same-facility revenue growth, quarter by quarter through 2027. Above 6%, the moat is intact and the SOTP rerate case stays alive. Between 4-6%, Tenet is roughly SGRY-equivalent and the consolidated 6× multiple is fair. Below 4% sustained, the physician-network moat is eroding — the most likely cause would be Optum/SCA narrow-network exclusions or HCA Sarah Cannon winning physician partnerships in shared markets. That single variable maps to ~$8-10B of equity value swing in the SOTP framework.